Solid Biosciences Advances Duchenne Screening with RUSP Inclusion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 16 2025
0mins
Source: Globenewswire
- Policy Advancement: The U.S. Department of Health and Human Services has added Duchenne muscular dystrophy to the Recommended Uniform Screening Panel, which is expected to accelerate early detection and improve treatment outcomes for patients.
- Industry Collaboration: Solid Biosciences, as a member of the Parent Project Muscular Dystrophy committee, has been instrumental in implementing newborn screening, highlighting the company's leadership and influence in the industry.
- Technological Innovation: The company is advancing its SGT-003 gene therapy, designed to improve muscle blood flow and reduce fatigue through a unique microdystrophin construct, potentially positioning it as a best-in-class treatment for Duchenne.
- Market Potential: With an incidence rate of one in every 3,500 to 5,000 male births in the U.S., the new policy is expected to benefit more families, further enhancing Solid's market share in the gene therapy sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLDB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLDB
Wall Street analysts forecast SLDB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLDB is 14.88 USD with a low forecast of 9.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.600
Low
9.00
Averages
14.88
High
20.00
Current: 6.600
Low
9.00
Averages
14.88
High
20.00
About SLDB
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sarepta Shares Rise as 3-Year Elevidys Study Results Offer Promise.
- Positive Study Results: Sarepta Therapeutics announced positive top-line results for its study on Elevidys, a treatment for Duchenne muscular dystrophy.
- Stock Market Reaction: Following the announcement, Sarepta's stock experienced a significant increase.
Continue Reading
Solid Biosciences (SLDB) Completes Enrollment for SGT-003 Clinical Trial
- Trial Enrollment Completed: Solid Biosciences announced full enrollment in its Phase 1/2 study for SGT-003 targeting Duchenne muscular dystrophy, with an expected 50-60 patients, indicating significant progress in the gene therapy sector.
- Patient Safety Update: As of January 9, 2025, 33 patients have received SGT-003, showing general tolerability, which enhances confidence in its safety profile, following a previous update on 23 patients' positive responses.
- FDA Interaction Progress: The company expects to provide updates on the Phase 3 confirmatory trial design for SGT-003 by mid-2026, which will offer crucial guidance for future clinical development and may expedite the drug's market entry.
- Positive Market Reaction: Following the enrollment announcement, Solid Biosciences' stock rose on Wednesday, reflecting investor optimism regarding the company's prospects in treating muscle-wasting disorders, potentially driving future funding and partnership opportunities.
Continue Reading